Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Male or female patients~2. Diagnosis of Cystic Fibrosis (positive sweat chloride test or two identifiable mutations)~3. Pre-bronchodilator FEV1 greater/equal 25% of predicted values~Exclusion criteria:~1. Significant history of allergy/hypersensitivity~2. Hypersensitivity to study drug~3. Participation in another trial~4. Female patients who are pregnant or lactating~5. Female patients of childbearing potential~6. Patients who have started a new medication for CF within 4 weeks of screening~7. Patients with known substance abuse~8. Clinically significant disease other than CF

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tiotropium Respimat 2.5 mcg (Type: EXPERIMENTAL): patient to receive low dose tiotropium once daily
- Tiotropium Respimat 5 mcg (Type: EXPERIMENTAL): patient to receive high dose tiotropium once daily
- Placebo Respimat (Type: PLACEBO_COMPARATOR): patient to receive placebo once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).